Dysentery disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DYS015 MIFTS: 52	Dysentery Categories: Blood diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery ¹¹ ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Infectious Diarrhea ¹¹ ⁵³ ⁶³

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases Blood diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:12384

ICD9CM ³⁴ 009.2

MeSH ⁴³ D004403

SNOMED-CT ⁶⁸ 154268000

EFO ¹⁶ EFO_1001869

UMLS ⁷¹ C0013369

Sources

Summaries for Dysentery

PubMed Health : ⁶³ Infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary: Dysentery, also known as infectious diarrhea, is related to shigellosis and campylobacteriosis, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Loperamide and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and small intestine, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology: ¹¹ An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia: ⁷⁵ Dysentery (UK pronunciation: /ˈdɪsəntri/, US: /ˈdɪsəntɛri/), historically known as the bloody flux, is a... more...

Sources

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 918)

#	Related Disease	Score	Top Affiliating Genes
1	shigellosis	32.3	STX2 STX1A ST8SIA2 LTF IL1B IL1A
2	campylobacteriosis	32.0	STX2 STX1A ST8SIA2 IL10
3	amebiasis	31.8	TNF IL6 IL1B IL10 CXCL8 ALB
4	schistosomiasis	31.8	TNF IL1A IL10 CRP ALB
5	parasitic helminthiasis infectious disease	31.6	TNF IL6 IL1B IL10 CCR6 ALB
6	diarrhea	31.2	TTR TNF IL6 IL1B IL10 IFNA2
7	typhoid fever	31.2	TNF IL6 IL1B IL1A CRP CCR6
8	paratyphoid fever	31.1	TNF IL1B IL1A CRP
9	keratoconjunctivitis	31.0	TNF LTF IL1A ALB
10	epidemic typhus	30.9	IL10 CRP ALB
11	inflammatory bowel disease 1	30.8	TNF IL6 IL1B IL10 CCR6
12	trichuriasis	30.8	TNF IL10 CXCL8
13	cholera	30.8	TNF TF IL6 IL1B IL10 CXCL8
14	salmonellosis	30.7	TNF IL6 IL1B IL10 CXCL8 CCR6
15	enterocolitis	30.7	TNF IL6 IL10 CXCL8 CRP
16	reactive arthritis	30.6	TNF LTF HP CRP CCR6
17	hemolytic uremic syndrome, atypical 1	30.6	ST8SIA2 HP CRP ALB
18	viral hepatitis	30.5	IL6 IFNA2 CRP ALB
19	nutritional deficiency disease	30.5	TTR TF IL6 CRP CCR6 ALB
20	ulcerative colitis	30.5	TNF IL6 IL1B IL10 CXCL8 CRP
21	toxic megacolon	30.4	TNF CRP CCR6 ALB
22	protein-losing enteropathy	30.4	TTR CRP ALB
23	iron metabolism disease	30.4	TTR TF CRP
24	disseminated intravascular coagulation	30.4	TNF IL6 IL10 CRP
25	gastroenteritis	30.4	TNF IL6 IL1B IL10 IFNA2 CXCL8
26	cholecystitis	30.4	HP CRP ALB
27	intussusception	30.4	IL6 CRP ALB
28	gallbladder disease	30.4	IL6 CRP CCR6 ALB
29	acute kidney failure	30.3	IL6 HP ALB
30	sleeping sickness	30.3	TNF TF IL10 HP ALB
31	syphilis	30.3	TNF CRP CCR6 ALB
32	irritable bowel syndrome	30.3	TNF IL6 IL1B IL10 CXCL8 CRP
33	scarlet fever	30.3	TNF IL6 IL1B CRP ALB
34	tetanus	30.3	TNF IL6 IL1B IL1A IL10 CRP
35	alcohol dependence	30.2	TNF TF IL1B IL1A ALB
36	lactose intolerance	30.2	TNF IL6 IL10 CRP ALB
37	guillain-barre syndrome	30.2	TNF HP ALB
38	parotitis	30.2	LTF CRP ALB
39	appendicitis	30.2	TNF IL6 IL1B IL10 ENO2 CXCL8
40	cystitis	30.2	TNF IL6 CXCL8 CRP
41	colitis	30.2	TNF LTF IL6 IL1B IL10 CXCL8
42	abdominal tuberculosis	30.2	TNF CRP ALB
43	immunoglobulin alpha deficiency	30.2	IL10 HP CCR6
44	pleural empyema	30.2	IL6 CRP ALB
45	adult syndrome	30.2	TNF IL6 CRP
46	pasteurellosis	30.1	HP CXCL8 ALB
47	liver cirrhosis	30.1	TTR TNF TF IL6 HP ALB
48	acute diarrhea	30.1	STX2 STX1A ST8SIA2 IL10 CXCL8 CRP
49	angina pectoris	30.1	TNF IL6 CRP
50	bowel dysfunction	30.1	TNF LTF IL6 IL1B IL10 CRP

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:

Sources

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:

diarrhea

GenomeRNAi Phenotypes related to Dysentery according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.14	ALB CCR6 CRP CXCL8 ENO2 HP
2	no effect	GR00402-S-2	10.14	ALB CCR6 CRP HP IFNA2 IL10

MGI Mouse Phenotypes related to Dysentery:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10	ALB CCR6 CRP HP IL10 IL1A
2	neoplasm	MP:0002006	9.86	ALB HP IL10 IL1A IL1B IL6
3	cardiovascular system	MP:0005385	9.7	ALB CCR6 CRP HP IL10 IL1A
4	immune system	MP:0005387	9.4	ALB CCR6 CRP HP IFNA2 IL10

Sources

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: ⁶³

You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Loperamide

Approved

Phase 4

53179-11-6

3955

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Mebendazole

Approved, Vet_approved

Phase 4

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 4

110-85-0

4837

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1, 93107-08-5

2764

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Antidiarrheals

Phase 4

Antimitotic Agents

Phase 4

Anthelmintics

Phase 4

Antiparasitic Agents

Phase 4

Tubulin Modulators

Phase 4

Citrate

Phase 4

Piperazine citrate

Phase 4

DMP 777

Phase 4

157341-41-8

Anti-Retroviral Agents

Phase 4

Fluoroquinolones

Phase 4

Rifamycin

Approved, Investigational

Phase 3

6998-60-3

6324616

Zinc cation

Approved, Experimental, Investigational

Phase 3

7440-66-6, 23713-49-7

32051

Nitazoxanide

Approved, Investigational, Vet_approved

Phase 3

55981-09-4

41684

Aluminium phosphate

Approved, Investigational

Phase 3

7784-30-7

Immunologic Factors

Phase 3

Antirheumatic Agents

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Trace Elements

Phase 3

Micronutrients

Phase 3

Rifamycins

Phase 3

422447

Auranofin

Approved, Investigational

Phase 2

34031-32-8

6918453 16667669 70788951

Histamine

Approved, Investigational

Phase 2

51-45-6

774

Aluminum hydroxide

Approved, Investigational

Phase 2

21645-51-2

Azithromycin

Approved

Phase 2

83905-01-5

447043

Ceftriaxone

Approved

Phase 2

73384-59-5

5479530

Inulin

Approved, Investigational, Nutraceutical

Phase 1, Phase 2

9005-80-5

24763

Butyric Acid

Experimental, Investigational

Phase 2

107-92-6

264

Complement System Proteins

Phase 1, Phase 2

Complement Factor H

Phase 1, Phase 2

Immunosuppressive Agents

Phase 1, Phase 2

Neurotransmitter Agents

Phase 2

Histamine phosphate

Phase 2

51-74-1

134614

Histamine Antagonists

Phase 2

Acidophilus

Phase 1, Phase 2

Anti-Ulcer Agents

Phase 2

Adjuvants, Immunologic

Phase 2

Antacids

Phase 2

Antibiotics, Antitubercular

Phase 2

Cephalosporins

Phase 2

beta-Lactams

Phase 2

Lactams

Phase 2

Pharmaceutical Solutions

Phase 2

Interventional clinical trials:

(show top 50) (show all 92)

#	Name	Status	NCT ID	Phase	Drugs
1	Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study	Completed	NCT00490932	Phase 4	Hypo-osmolar ORS
2	Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population	Completed	NCT02385058	Phase 4	Mebendazole;Quinfamide;Placebo
3	Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea	Completed	NCT00292344	Phase 4	Rifaximin and loperamide
4	A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea	Completed	NCT04192487	Phase 4	Crofelemer delayed-release tablets 125mg
5	An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam	Recruiting	NCT03854929	Phase 4	Ciprofloxacin;Azithromycin
6	A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea	Terminated	NCT01005849	Phase 4
7	Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea	Withdrawn	NCT00875875	Phase 4	Rifaximin
8	Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni	Completed	NCT02280044	Phase 2, Phase 3
9	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea	Completed	NCT01142089	Phase 3	Placebo;Rifamycin SV MMX
10	A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System	Completed	NCT00993681	Phase 3
11	Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery	Completed	NCT00321126	Phase 3	Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
12	Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children	Completed	NCT00366730	Phase 3	Nitazoxanide
13	Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents	Completed	NCT00366236	Phase 3	Nitazoxanide
14	Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel	Completed	NCT00368316	Phase 3
15	A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers	Completed	NCT01208922	Phase 3	Rifamycin SV-MMX®;Ciprofloxacin
16	A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years	Recruiting	NCT05156528	Phase 3
17	A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea	Terminated	NCT02920242	Phase 3	Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
18	Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea	Withdrawn	NCT02736539	Phase 3	CBS 2004 (galacto-oligosaccharides);Placebo
19	A Randomized, Blinded, Single-center, Parallel Controlled , Phase Ⅱ Clinical Trial to Evaluate Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged From 3 Months to 5 Years Old	Completed	NCT04865497	Phase 2
20	Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa	Completed	NCT02736968	Phase 2	Auranofin
21	Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults	Completed	NCT03527173	Phase 2	Placebo
22	Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults	Completed	NCT01080716	Phase 1, Phase 2
23	A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis	Completed	NCT02676895	Phase 2
24	Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a	Completed	NCT02646371	Phase 2
25	Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection	Completed	NCT00485134	Phase 1, Phase 2
26	Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis	Completed	NCT00800930	Phase 2
27	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults	Completed	NCT00751777	Phase 2
28	Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity	Completed	NCT01034228	Phase 2
29	Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants	Completed	NCT04056117	Phase 1, Phase 2
30	Probiotics for Infectious Diarrhea in Children in South India	Completed	NCT01130792	Phase 1, Phase 2
31	A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia	Completed	NCT01040325	Phase 2
32	A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers	Completed	NCT00210288	Phase 2
33	Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study	Completed	NCT03447821	Phase 2	400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
34	Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection	Recruiting	NCT04078022	Phase 2
35	A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.	Active, not recruiting	NCT04602975	Phase 2
36	A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults	Not yet recruiting	NCT04242264	Phase 2
37	A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis With Shigella Flexneri 2a Strain	Not yet recruiting	NCT05182749	Phase 1, Phase 2
38	Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Not yet recruiting	NCT04026984	Phase 2	Rifamycin SV-MMX;Placebo
39	Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years	Not yet recruiting	NCT04027894	Phase 2	Rifamycin SV MMX;Placebo to Rifamycin SV-MMX
40	Tebipenem-pivoxil as an Alternative to Ceftriaxone for Clinically Non-responding Children With Shigellosis: a Randomized Non-inferiority Trial	Not yet recruiting	NCT05121974	Phase 2	Tebipenem Pivoxil;Azithromycin;Ceftriaxon
41	Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study	Terminated	NCT00866476	Phase 2
42	Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study	Terminated	NCT00866242	Phase 2
43	A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects	Withdrawn	NCT03038243	Phase 2
44	A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months	Completed	NCT03561181	Phase 1
45	A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers	Completed	NCT02797236	Phase 1
46	A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study	Completed	NCT03089879	Phase 1
47	A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity	Completed	NCT02445963	Phase 1
48	An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects	Completed	NCT02089048	Phase 1	Auranofin
49	A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults.	Completed	NCT02017899	Phase 1
50	A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults.	Completed	NCT02034500	Phase 1

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Ciprofloxacin

Scopolamine

Scopolamine Hydrobromide

Cochrane evidence based reviews: dysentery

Sources

Genetic Tests for Dysentery

Sources

Anatomical Context for Dysentery

Organs/tissues related to Dysentery:

MalaCards : Colon, Liver, Small Intestine, Neutrophil, Lymph Node, Skin, Bone Marrow

Sources

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8927)

#	Title	Authors	PMID	Year
1	Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. ⁵³ ⁶²	Shastri YM...Stein J	19028207	2008
2	Antibiotics for the empirical treatment of acute infectious diarrhea in children. ⁵³ ⁶²	Diniz-Santos DR...Silva N	17568855	2006
3	Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway. ⁶²	Liao W...Zeng J	36328204	2023
4	Botany, ethnopharmacology, phytochemistry and pharmacology of Erodii Herba Geranii Herba-An review. ⁶²	Kong C...Liu Y	36341816	2023
5	Deciphering the underlying wound healing mechanisms of Streptocaulon juventas (Lour.) Merr. by integrating network pharmacology, transcriptomics, and experimental validation. ⁶²	Li Y...Qiu F	36336222	2023
6	Citrate and hydroxycinnamate derivatives from Mume Fructus protect LPS-injured intestinal epithelial cells by regulating the FAK/PI3K/AKT signaling pathway. ⁶²	Liu Z...Li X	36270558	2023
7	A comparative study of Liandan Xiaoyan Formula metabolic profiles in control and colitis rats by UPLC-Q-TOF-MS combined with chemometrics. ⁶²	Wang Q...Zhu C	36332331	2023
8	A review on the traditional uses, phytochemistry, and pharmacology of the genus Veronicastrum (Plantaginaceae). ⁶²	Mutinda ES...Hu GW	36108894	2023
9	Geographical variation in the effect of ambient temperature on infectious diarrhea among children under 5 years. ⁶²	Zheng H...Xia Y	36208789	2023
10	In vitro evaluation of gentamicin activity against Spanish field isolates of Brachyspira hyodysenteriae. ⁶²	Vega C...Carvajal A	36451249	2022
11	Discovery of metabolic markers for the discrimination of Helwingia species based on bioactivity evaluation, plant metabolomics, and network pharmacology. ⁶²	Wang C...Han L	36195983	2022
12	Bacteriophages: An Alternative to Combat Antibiotic Resistance? ⁶²	Gupta M...Burkhart C	36468950	2022
13	Computational characterization of homologous ligands binding to a deep hydrophobic pocket in Shigella flexneri pilot protein MxiM. ⁶²	Zhu S	35871311	2022
14	Hypothetical proteins play a role in stage conversion, virulence, and the stress response in the Entamoeba species. ⁶²	Walters HA...Temesvari LA	36309065	2022
15	Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021. ⁶²	Bagamian KH...Scheele S	36237199	2022
16	Sleep duration prior to an enterotoxigenic Escherichia coli challenge predicts diarrhea severity during infection. ⁶²	Mantua J...Porter CK	36240601	2022
17	Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. ⁶²	Maqbool S...Lee KY	36460884	2022
18	Colonic innate immune defenses and microbiota alterations in acute swine dysentery. ⁶²	Fodor CC...Cobo ER	36371065	2022
19	The size of the susceptible pool differentiates climate effects on seasonal epidemics of bacillary dysentery. ⁶²	Ni H...Zhou H	36455742	2022
20	Impatiens balsamina: An updated review on the ethnobotanical uses, phytochemistry, and pharmacological activity. ⁶²	Qian H...Zhao Y	36436713	2022
21	Alternanthera sessilis: Uncovering the nutritional and medicinal values of an edible weed. ⁶²	Hwong CS...Kong KW	35973630	2022
22	Diagnostic testing practices for diarrhoeal cases in South African public hospitals. ⁶²	Johnstone SL...Thomas J	36352368	2022
23	Polysaccharides from Tetrastigma Hemsleyanum Diels et Gilg attenuate LPS-induced acute lung injury by modulating TLR4/COX-2/NF-κB signaling pathway. ⁶²	Wang B...Zhou F	36182735	2022
24	Chemical constituents from the seed husks of Oryza sativa L. ⁶²	Ali M...Mir SR	34963398	2022
25	GC-MS Analysis of Bioactive Compounds of Flower Extracts of Calycopteris floribunda Lam.: A Multi Potent Medicinal Plant. ⁶²	Yarazari SB...Jayaraj M	35689756	2022
26	Multi-omics analysis to characterize molecular adaptation of Entamoeba histolytica during serum stress. ⁶²	Singh SS...Bhattacharya S	36066285	2022
27	Cysteine-Dependent Conformational Heterogeneity of Shigella flexneri Autotransporter IcsA and Implications of Its Function. ⁶²	Qin J...Totsika M	36374106	2022
28	A systematic review of tools for predicting complications in patients with acute infectious diarrhea. ⁶²	Marx T...Berthelot S	36469970	2022
29	Occurrence and Characteristics of Escherichia albertii in Wild Birds and Poultry Flocks in Switzerland. ⁶²	Barmettler K...Stephan R	36422334	2022
30	Common Etiological Agents in Adult Patients with Gastroenteritis from Central Iran. ⁶²	Abbasi E...Ghaznavi-Rad E	36130139	2022
31	Analysis of the epidemiological characteristics between 2004 and 2017 and prediction of the changing pattern of other infectious diarrhea (OID) under COVID-19 in China. ⁶²	Ge Y...Xu L	36281122	2022
32	Three metal complexes with a pyridyl Schiff base: cytotoxicity, migration and mechanism of apoptosis. ⁶²	Zhou F...Liang L	36111968	2022
33	Bacteroides thetaiotaomicron Outer Membrane Vesicles Modulate Virulence of Shigella flexneri. ⁶²	Xerri NL...Payne SM	36102517	2022
34	Quality consistency evaluation on three species of North Patrininae herba by high-performance liquid chromatography coupled with electrospray ion trap time-of-flight mass spectrometry and network pharmacology approaches. ⁶²	Sun Q...Lin Y	35988143	2022
35	Dynamics of the Gut Microbiome in Shigella-Infected Children during the First Two Years of Life. ⁶²	Ndungo E...Rasko DA	36121169	2022
36	[Evaluation of the Methods Used for the Detection of Entamoeba histolytica in Stool Samples of Patients with Diarrhea]. ⁶²	Tortop S...Ogunc D	36458714	2022
37	Tapinanthus species: A review of botany and biology, secondary metabolites, ethnomedical uses, current pharmacology and toxicology. ⁶²	Wang L...Zhou H	35714877	2022
38	Morinda umbellata active fraction inhibits lipopolysaccharide induced proinflammatory cytokines by downregulating NF-κB activation. ⁶²	Krishnakumar NM...Ceasar SA	36337241	2022
39	Isolation and Genetic Characterization of a Bovine Coronavirus KBR-1 Strain from Calf Feces in South Korea. ⁶²	Shin J...An DJ	36366474	2022
40	Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. ⁶²	Zhang X...Shen T	35644437	2022
41	Holm Oak (Quercus ilex subsp. ballota (Desf.) Samp.) Bark Aqueous Ammonia Extract for the Control of Invasive Forest Pathogens. ⁶²	Sanchez-Hernandez E...Martin-Ramos P	36233184	2022
42	The Therapeutic Efficacy of Punica granatum and Its Bioactive Constituents with Special Reference to Photodynamic Therapy. ⁶²	Fakudze NT...Abrahamse H	36365273	2022
43	Hypericumsampsonii attenuates inflammation in mice with ulcerative colitis via regulation of PDE4/PKA/CREB signaling pathway. ⁶²	Lin Y...Sun Z	35688258	2022
44	Choline, DHA, and Diarrheal Disease Associated with Growth Faltering in a Case-Control Study. ⁶²	Diaz JN...Iannotti LL	36204326	2022
45	Clostridium difficile colitis portends poor outcomes in lower extremity orthopaedic trauma surgery. ⁶²	Gonzalez CA...Gardner MJ	36002345	2022
46	[Analysis of epidemiological characteristics of bacillary dysentery with multiple-onset in Henan Province from 2005 to 2020]. ⁶²	Li YF...Huang XY	36274616	2022
47	First report and genomic characterization of a bovine-like coronavirus causing enteric infection in an odd-toed non-ruminant species (Indonesian tapir, Acrocodia indica) during an outbreak of winter dysentery in a zoo. ⁶²	Savard C...Wang L	34427399	2022
48	In Vitro Screening of Non-Antibiotic Components to Mitigate Intestinal Lesions Caused by Brachyspira hyodysenteriae, Lawsonia intracellularis and Salmonella enterica Serovar Typhimurium. ⁶²	de Groot N...de O Costa M	36139216	2022
49	Elucidation of Key Interactions between VirF and the virB Promoter in Shigella flexneri Using E. coli MarA- and GadX-Based Homology Models and In Vitro Analysis of the DNA-Binding Domains of VirF and MarA. ⁶²	Ragazzone NJ...Garcia GA	36040161	2022
50	Study on the mechanism of Huangqin Decoction on rats with ulcerative colitis of damp-heat type base on mtDNA, TLR4, p-PI3K, p-Akt protein expression and microbiota. ⁶²	Zheng Y...Yuan X	35568112	2022

Sources

Genes for Dysentery

Genes related to Dysentery (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ALB	Albumin	Protein Coding	13.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	CRP	C-Reactive Protein	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	IL1A	Interleukin 1 Alpha	Protein Coding	12.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	HP	Haptoglobin	Protein Coding	11.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	TTR	Transthyretin	Protein Coding	11.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	TF	Transferrin	Protein Coding	11.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	TMPO	Thymopoietin	Protein Coding	10.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	IFNA2	Interferon Alpha 2	Protein Coding	10.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	LTF	Lactotransferrin	Protein Coding	8.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19028207
10	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.57	DISEASES inferred ¹⁴ ¹⁴
11	IL1RAPL2	Interleukin 1 Receptor Accessory Protein Like 2	Protein Coding	7.4	GeneCards inferred via : Publications (show sections)
12	ENO2	Enolase 2	Protein Coding	7.23	GeneCards inferred via : Publications (show sections)
13	STX2	Syntaxin 2	Protein Coding	7.06	DISEASES inferred ¹⁴
14	ST8SIA2	ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 2	Protein Coding	7.06	DISEASES inferred ¹⁴
15	STX1A	Syntaxin 1A	Protein Coding	7.04	DISEASES inferred ¹⁴
16	IL1B	Interleukin 1 Beta	Protein Coding	6.57	DISEASES inferred ¹⁴
17	TNF	Tumor Necrosis Factor	Protein Coding	6.54	DISEASES inferred ¹⁴
18	IL6	Interleukin 6	Protein Coding	6.47	DISEASES inferred ¹⁴
19	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.21	DISEASES inferred ¹⁴
20	IL10	Interleukin 10	Protein Coding	6.2	DISEASES inferred ¹⁴
21	H2AC18	H2A Clustered Histone 18	Protein Coding	6.08	DISEASES inferred ¹⁴ ¹⁴
22	CD4	CD4 Molecule	Protein Coding	6.01	DISEASES inferred ¹⁴
23	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6	DISEASES inferred ¹⁴
24	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	5.99	DISEASES inferred ¹⁴
25	SERPINA3	Serpin Family A Member 3	Protein Coding	5.87	DISEASES inferred ¹⁴ ¹⁴
26	STH	Saitohin	Protein Coding	5.81	DISEASES inferred ¹⁴
27	TLR4	Toll Like Receptor 4	Protein Coding	5.8	DISEASES inferred ¹⁴
28	SLC9A3	Solute Carrier Family 9 Member A3	Protein Coding	5.79	DISEASES inferred ¹⁴
29	CASP3	Caspase 3	Protein Coding	5.75	DISEASES inferred ¹⁴
30	MGAM	Maltase-Glucoamylase	Protein Coding	5.75	DISEASES inferred ¹⁴
31	MT-TH	Mitochondrially Encoded TRNA-His (CAU/C)	RNA Gene	5.74	DISEASES inferred ¹⁴
32	SI	Sucrase-Isomaltase	Protein Coding	5.7	DISEASES inferred ¹⁴
33	OCLN	Occludin	Protein Coding	5.7	DISEASES inferred ¹⁴

Sources

Variations for Dysentery

Sources

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Sources

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

(show all 48)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.96	TTR TNF STX1A LTF IL6 IL1B
2	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.39	TNF IL6 IL1B IL1A IL10 CXCL8
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.34	TNF STX1A IL6 IL1B IL1A IL10
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.3	TNF IL6 IL1B IL1A IL10 CXCL8
5	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.87	TNF IL6 IL1B IL1A IFNA2 CXCL8
6	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.66	CXCL8 IFNA2 IL10 IL1A IL1B IL6
7	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.63	TNF IL6 IL1B IL1A CXCL8
8	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.54	TNF IL6 IL1B IFNA2 CXCL8
9	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.44	CXCL8 IL1A IL1B IL6 TNF
10	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.35	TNF IL6 IL1B IL1A CXCL8
11	Neuroinflammation and glutamatergic signaling ⁷⁴	12.13	IL10 IL1A IL1B IL6 TNF
12	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.03	IFNA2 IL10 IL6 TNF
13	Spinal cord injury ⁷⁴	12.03	TNF IL6 IL1B IL1A CXCL8
14	Senescence and autophagy in cancer ⁷⁴	11.98	IL6 IL1B IL1A CXCL8
15	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.95	IL10 IL1B IL6 TNF
16	CCL18 signaling pathway ⁷⁴	11.92	IL6 IL10 CXCL8 CCR6
17	Allograft rejection ⁷⁴	11.9	TNF IL1B IL1A IL10 CXCL8
18	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.88	CXCL8 IL10 IL1A IL1B IL6 TNF
19	Innate Lymphoid Cells Differentiation ⁶⁵	11.83	TNF IL1B IL10 CCR6
20	Burn wound healing ⁷⁴	11.78	CXCL8 IFNA2 IL1B IL6 TNF
21	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.77	TNF IL6 IL10 CRP
22	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.76	IL6 CXCL8 CRP
23	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.76	TNF IL6 IL1B IL10 IFNA2
24	Lung fibrosis ⁷⁴	11.72	TNF IL6 IL1B CXCL8
25	AP-1 transcription factor network ⁶¹	11.71	IL6 IL10 CXCL8
26	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.7	TNF TF IL6 IL1B IL1A IL10
27	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.68	TNF IL6 IL1A IL10
28	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.65	TNF IL6 IL1B IL1A CXCL8
29	miRNAs involvement in the immune response in sepsis ⁷⁴	11.62	TNF IL6 IL1A IL10 CXCL8
30	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.6	TNF IL6 IFNA2 CXCL8
31	IL 10 signaling pathway ⁶⁷	11.59	TNF IL6 IL1B IL1A IL10
32	Netrin-UNC5B signaling pathway ⁷⁴	11.58	TNF IL1A IL10
33	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.57	TNF IL10 CXCL8
34	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.53	TNF IL6 IL1B IL1A
35	Nonalcoholic fatty liver disease ⁷⁴	11.52	IL1A IL6 TNF
36	Monoamine transport ⁷⁴ Show member pathways Serotonin transporter activity ⁷⁴	11.49	TNF STX1A IL1B
37	Development and heterogeneity of the ILC family ⁷⁴	11.36	TNF IL6 IL1B
38	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.33	TNF IL6 IL1B CXCL8
39	Immune infiltration in pancreatic cancer ⁷⁴	11.26	TNF IL6 IL10 CXCL8
40	IL-10 Pathway ⁶⁴	11.26	TNF IL6 IL1B IL1A IL10
41	LDL- influence on CD14 and TLR4 ⁷⁴	11.13	IL6 IL1B IL10
42	Cytokines and inflammatory response ⁷⁴	11.12	TNF IL6 IL1B IL1A IL10
43	Overview of nanoparticle effects ⁷⁴	11.06	TNF IL6 CXCL8 CRP
44	G-protein signaling_Rap2B regulation pathway ²²	11.05	TNF IL6 IL1B IL1A IL10 CXCL8
45	Prostaglandin signaling ⁷⁴	11	TNF IL6 IL1B IL1A CXCL8
46	Interleukin-10 signaling ⁶⁶	10.77	TNF IL6 IL1B IL1A IL10 CXCL8
47	COVID-19 adverse outcome pathway ⁷⁴	10.7	IL6 CXCL8
48	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.43	TNF IL6 CXCL8

Sources

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.1	ALB CRP CXCL8 HP IFNA2 IL10
2	extracellular space	GO:0005615	9.8	ALB CRP CXCL8 ENO2 HP IFNA2
3	recycling endosome	GO:0055037	9.76	TNF TF ST8SIA2 LTF

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

(show all 33)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.35	TNF IL6 IL1B IL1A IL10 CXCL8
2	inflammatory response	GO:0006954	10.25	CRP CXCL8 IFNA2 IL1A IL1B IL6
3	defense response to Gram-positive bacterium	GO:0050830	10.24	CRP IL1B IL6 TNF
4	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.23	TNF IL6 IL1B IL10
5	positive regulation of interleukin-6 production	GO:0032755	10.19	IL1A IL1B IL6 TNF
6	cytokine-mediated signaling pathway	GO:0019221	10.18	IFNA2 IL1A IL1B IL1RAPL2 IL6
7	immune response	GO:0006955	10.16	TNF IL6 IL1B IL1A IL10 CXCL8
8	retina homeostasis	GO:0001895	10.13	TF LTF ALB
9	acute-phase response	GO:0006953	10.11	IL6 HP CRP
10	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.1	IL10 IL6 TNF
11	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001240	10.09	IL1A IL1B TNF
12	positive regulation of mitotic nuclear division	GO:0045840	10.08	TNF IL1B IL1A
13	positive regulation of chemokine production	GO:0032722	10.06	TNF IL6 IL1B
14	liver regeneration	GO:0097421	10.06	TNF IL6 IL10
15	positive regulation of vascular endothelial growth factor production	GO:0010575	10.05	IL6 IL1B IL1A
16	positive regulation of cytokine production	GO:0001819	10.05	TNF IL1B IL1A IL10
17	defense response	GO:0006952	10.03	TNF IFNA2 HP CXCL8
18	negative regulation of neurogenesis	GO:0050768	10.02	IL1B IL6 TNF
19	positive regulation of glial cell proliferation	GO:0060252	9.97	TNF IL6 IL1B
20	regulation of insulin secretion	GO:0050796	9.97	TNF STX1A IL6 IL1B
21	negative regulation of cytokine production involved in immune response	GO:0002719	9.96	TNF IL10
22	positive regulation of fever generation	GO:0031622	9.95	TNF IL1B
23	acute inflammatory response	GO:0002526	9.92	TNF IL1A HP
24	sequestering of triglyceride	GO:0030730	9.91	TNF IL1B
25	positive regulation of heterotypic cell-cell adhesion	GO:0034116	9.91	TNF IL1B IL10
26	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.87	TNF IL1B
27	fever generation	GO:0001660	9.86	IL1B IL1A
28	chronic inflammatory response to antigenic stimulus	GO:0002439	9.84	TNF IL10
29	positive regulation of neuroinflammatory response	GO:0150078	9.8	TNF IL6 IL1B
30	negative regulation of lipid storage	GO:0010888	9.73	TNF IL6 CRP
31	cellular response to lipopolysaccharide	GO:0071222	9.7	TNF IL6 IL1B IL1A IL10 CXCL8
32	vascular endothelial growth factor production	GO:0010573	9.63	IL1B IL6 TNF
33	humoral immune response	GO:0006959	9.32	TNF LTF IL6 IFNA2 CCR6